BIOXYTRAN, INC
BIXT evidence brief
What we can confirm
- BioSniper Score:
- 2.9 / 10
- Market Cap:
- $2.7M
- Lead Asset:
- BXT-25 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for BIXT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BIXT
BIOXYTRAN, Inc. (BIXT) is a clinical-stage pharmaceutical company developing oxygen-transport therapeutics for hypoxia-related conditions, including stroke and COVID-19, with a pipeline centered on ProLectin-M and BXT-25.
Key risk: Insufficient capital
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.7M
Cash Runway
—
Lead Asset
BXT-25 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for BIOXYTRAN, INC.
Similar companies
BIOXYTRAN, Inc. (BIXT) is a clinical-stage pharmaceutical company developing oxygen-transport therapeutics for hypoxia-related conditions, including stroke and COVID-19, with a pipeline centered on ProLectin-M and BXT-25.
- Clinical-stage company founded in 2008, reorganized in 2018 to focus on hypoxia therapeutics [sec · filed 2025-01-13].
- FDA-approved IND for ProLectin-M (PROTECT trial) targeting COVID-19; trial start dates have been repeatedly deferred [sec_mda · as of 2026-08-14].
- BXT-25, an acellular oxygen carrier, showed non-toxicity in animal testing [sec_mda · as of 2026-08-14].
- Net loss of $0.6M and negative shareholders' equity of $4.9M as of 2026-06-30 [sec].
- Company states it does not have sufficient capital to fund operations and needs $3.7M for 15 months of working capital [sec_mda · as of 2026-08-14].
What works
- FDA has approved an IND for ProLectin-M, allowing a U.S. clinical trial to proceed [sec_mda · as of 2026-08-14].
- BXT-25 animal studies showed non-toxicity and full recovery, supporting further development [sec_mda · as of 2026-08-14].
- Company has an active pipeline addressing multiple indications (stroke, COVID-19, lung fibrosis) [sec_mda · as of 2026-08-14].
What to weigh
- Company repeatedly states it lacks sufficient capital to fund operations and relies on future fundraising [sec_mda · as of 2026-08-14].
- Shareholders' equity is negative ($4.9M as of 2026-06-30), indicating accumulated deficits exceed assets [sec].
- Clinical trial start dates for ProLectin-M have been repeatedly pushed back (from Q2 2025 to Q3 2026) [sec_mda · as of 2026-08-14].
- Net loss of $0.6M in the latest reported period (as of 2026-06-30) [sec].
From the filings
Quoted directly from source documents.
FDA IND approval for ProLectin-M
“On August 21, 2023, the Company's IND #153742 under the title "PROTECT: ProLectin-M, a nucleocapsid TErminal GaleCTin antagonist for COVID-19 (PROTECT), a Randomized, Double-blinded Clinical Trial to Evaluate the Efficacy and Safety in Non-Hospitalized Adult Participants with COVID-19" was approved by the FDA”
SEC MD&A · August 14, 2026
BXT-25 animal testing non-toxicity
“On April 19, 2023, the Company announced that its Acelluar Oxygen Carrier ("AOC") BXT-25 had been successfully tested in animals. The initial results are very encouraging because they show the non-toxicity of the experimental drug, along with the corresponding full recovery”
SEC MD&A · August 14, 2026
Insufficient capital to fund operations
“We do not currently have sufficient capital resources to fund operations.”
SEC MD&A · April 15, 2026
Need for $3.7M working capital
“We believe that if we can raise $3,700,000, we will have sufficient working capital to develop our business over the next approximately fifteen (15) months.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Insufficient capital — Company states it lacks sufficient capital to fund operations and needs $3.7M for 15 months [sec_mda · as of 2026-08-14].
- Negative equity — Shareholders' equity is -$4.9M as of 2026-06-30, indicating accumulated losses exceed assets [sec].
- Repeated trial delays — ProLectin-M trial start date has been deferred multiple times, now expected Q3 2026 [sec_mda · as of 2026-08-14].
- No approved products — Company has no marketed products and relies entirely on future clinical success and funding [sec_mda · as of 2026-08-14].
What to watch
- Publication of Phase 2 ProLectin-M trial results (expected within 90 days of August 2026) [sec_mda · as of 2026-08-14].
- Company's ability to raise the stated $3.7M working capital [sec_mda · as of 2026-08-14].
- Initiation of the FDA-approved PROTECT trial for ProLectin-M [sec_mda · as of 2026-08-14].
- Progress of BXT-25 toward clinical trials for stroke [sec_mda · as of 2026-08-14].
Sources: News · SEC filings · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run BIOXYTRAN, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIOXYTRAN, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$620K
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for BIOXYTRAN, INC?
BIOXYTRAN, Inc. (BIXT) is a clinical-stage pharmaceutical company developing oxygen-transport therapeutics for hypoxia-related conditions, including stroke and COVID-19, with a pipeline centered on ProLectin-M and BXT-25.
What is BIOXYTRAN, INC's lead drug candidate?
BIOXYTRAN, INC's most advanced tracked candidate is BXT-25 (Preclinical) for ischemic stroke.
Who is the CEO of BIOXYTRAN, INC?
Dr. David Platt Ph.D. is the chief executive officer of BIOXYTRAN, INC (BIXT).
Where is BIOXYTRAN, INC headquartered?
BIOXYTRAN, INC (BIXT) is headquartered in Needham, MA, United States.
What therapeutic areas does BIOXYTRAN, INC focus on?
BIOXYTRAN, INC develops therapies across Neurology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.